Bavarian Nordic A/S today announced the appointment of Henrik Juuel to the position of Executive Vice President and Chief Financial Officer. Mr. Juuel is currently the CFO of Orexo AB.
Brain disease specialist Denali Therapeutics will buy all outstanding shares in British F-Star Gamma Ltd from F-Star instead licencing bispecific antibody candidates that can cross the blood-brain barrier (BBB) co-developed under an agreement dating back to 2016.
Nordic Nanovector ASA today announces that Rainer Boehm, MD was elected as a member of its Board of Directors at the companys Annual General Meeting on 30 May 2018.
Roche announced that atezolimumab plus chemotherapy met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) as first-line treatment of stage IV nonsquamous non small cell lung cancer (NSCLC).
Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).
Interleukin 1 (IL-1) blockers may prevent serious adverse events triggered by CAR-T cell therapies, according to two independent studies.
Following reports of an increase in mortality in a study that combined Genmabs anti-CD38 daratumumab with a PD-L1 blocker, Genmabs partner Janssen has stopped a study combining daratumumab with its PD1 blocker JNJ-63723283 in multiple myeloma.
Targovax ASAs cancer immunotherapy TG01 significantly prolonged 2-year overall survival of patients with resected pancreatic cancer versus standard therapy. Targovax shares were up 16% on Thursday evening.
Italian oncologists have found a more effective tumour angiogenesis blocker which curbs metastasis and tumour growth.
Vifor Fresenius Medical Care Renal Pharma has licenced ex-US/Japanese/Korean rights to commercialise CR845 (difelikefalin) from Cara Therapeutics for the treatment of chronic kidney disease-associated pruritus (CKD-aP).